• 1. Development and optimization of a fluorescence polarization immunoassay for orbifloxacin in milk
  Tiejun Mi,Xiao Liang,Long Ding,Suxia Zhang,Sergei A. Eremin,Ross C. Beier,Jianzhong Shen,Zhanhui Wang Anal. Methods 2014 6 3849
• 2. Metabolomics-based screening analysis of PPCPs in water pretreated with five different SPE columns
  Weifeng Xue,Haiqin Zhang,Mengyao Liu,Xi Chen,Shuwen He,Yingqian Chu Anal. Methods 2021 13 4594
• 3. A comprehensive review on multi-colored emissive carbon dots as fluorescent probes for the detection of pharmaceutical drugs in water
  Sathish Rajendran,Varsha UshaVipinachandran,Kabir Hussain Badagoppam Haroon,Indhumathi Ashokan,Susanta Kumar Bhunia Anal. Methods 2022 14 4263
• 4. Recognition of quinolone antibiotics by the multidrug efflux transporter MexB of Pseudomonas aeruginosa
  Silvia Gervasoni,Giuliano Malloci,Andrea Bosin,Attilio V. Vargiu,Helen I. Zgurskaya,Paolo Ruggerone Phys. Chem. Chem. Phys. 2022 24 16566
• 5. High-flux smartphone-integrated lateral flow assay based on chrysanthemum-like Au@polydopamine for sensitive detection of enrofloxacin in milk
  Ganggang Zhang,Xiaocui Lai,Weihua He,Liu Su,Gan Zhang,Weihua Lai,Shengliang Deng Lab Chip 2023 23 3207

• Pesticide Chemicals Pesticide Active Ingredients Standard Substances
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Orbifloxacin (CAS No. 113617-63-3): A Comprehensive Overview

Orbifloxacin (CAS No. 113617-63-3) is a broad-spectrum fluoroquinolone antibiotic that has gained significant attention in the veterinary and pharmaceutical industries due to its potent antimicrobial properties. This compound is particularly effective against a wide range of Gram-positive and Gram-negative bacteria, making it a valuable tool in the treatment of various infections in animals. In this comprehensive overview, we will delve into the chemical structure, pharmacological properties, clinical applications, and recent research advancements of Orbifloxacin.

Chemical Structure and Properties

Orbifloxacin is a synthetic fluoroquinolone with the molecular formula C₁₉H₂₂FN₃O₄. It has a molecular weight of 377.40 g/mol and is characterized by its fluoroquinolone core structure, which is essential for its antibacterial activity. The compound is highly soluble in water and organic solvents, making it suitable for various formulations, including oral and injectable solutions. The chemical structure of Orbifloxacin includes a fluorine atom at the C-6 position and a cyclopropyl group at the C-8 position, which contribute to its enhanced stability and broad-spectrum activity.

Pharmacological Mechanism of Action

The primary mechanism of action of Orbifloxacin involves the inhibition of bacterial DNA gyrase and topoisomerase IV, two essential enzymes responsible for DNA replication, repair, and transcription. By interfering with these enzymes, Orbifloxacin disrupts the bacterial DNA replication process, leading to cell death. This mechanism makes it highly effective against both Gram-positive and Gram-negative bacteria, including multidrug-resistant strains.

Clinical Applications in Veterinary Medicine

Orbifloxacin is widely used in veterinary medicine for the treatment of bacterial infections in companion animals such as dogs and cats. It is particularly effective in treating respiratory tract infections, urinary tract infections, skin infections, and otitis externa. The compound's excellent tissue penetration and long half-life make it suitable for once-daily dosing regimens, improving patient compliance and treatment outcomes.

Safety Profile and Adverse Effects

The safety profile of Orbifloxacin is generally favorable when used according to recommended dosing guidelines. Common adverse effects include gastrointestinal disturbances such as vomiting and diarrhea. In rare cases, more serious side effects such as hepatotoxicity and phototoxicity have been reported. However, these adverse effects are typically dose-dependent and can be minimized by adhering to proper dosing protocols.

Recent Research Advancements

The ongoing research on Orbifloxacin continues to expand our understanding of its therapeutic potential and mechanisms of action. Recent studies have focused on optimizing its delivery methods to enhance bioavailability and reduce side effects. For example, a study published in the Journal of Veterinary Pharmacology and Therapeutics (2022) explored the use of nanotechnology to improve the oral bioavailability of Orbifloxacin. The results showed that nano-formulated Orbifloxacin had significantly higher bioavailability compared to conventional formulations.

In another study published in Antimicrobial Agents and Chemotherapy (2021), researchers investigated the potential synergistic effects of combining Orbifloxacin with other antibiotics to combat multidrug-resistant bacteria. The findings indicated that co-administration of Orbifloxacin with beta-lactam antibiotics could effectively reduce the minimum inhibitory concentration (MIC) values for several resistant strains.

FUTURE DIRECTIONS AND CONCLUSIONS

The future of Orbifloxacin-based therapies looks promising as researchers continue to explore new delivery methods and combination therapies to enhance its efficacy and safety profile. The development of novel formulations using nanotechnology holds significant potential for improving patient outcomes in both veterinary and human medicine.

In conclusion, Orbifloxacin (CAS No. 113617-63-3) is a versatile fluoroquinolone antibiotic with a well-established role in veterinary medicine. Its broad-spectrum activity, favorable pharmacokinetic properties, and ongoing research advancements make it an important tool in the fight against bacterial infections. As new formulations and combination therapies continue to emerge, the therapeutic potential of Orbifloxacin is likely to expand further.

• 124858-35-1(Nadifloxacin)
• 160738-57-8(Gatifloxacin)
• 151213-15-9(8-Desmethoxy-8-fluoro Moxifloxacin)
• 74011-58-8(1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid)
• 70458-96-7(Norfloxacin)
• 112811-59-3(Gatifloxacin)
• 151096-09-2(Moxifloxacin)
• 110871-86-8(Sparfloxacin)
• 186826-86-8(Moxifloxacin hydrochloride)
• 149676-40-4(Pefloxacin Mesylate Dihydrate)